Transcranial magnetic stimulation pioneer Neuronetics has picked up a new FDA clearance that builds its position in obsessive-compulsive disorder (OCD), a major new application of the technology.

CARY, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Greenbrook TMS NeuroHealth Centers, one of the leading providers of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today ...

RESEDA, CA – October 23, 2025 – PRESSADVANTAGE – Moment of Clarity has released a new resource titled “What to Know About TMS ...

SANTA ANA, CA – October 22, 2025 – PRESSADVANTAGE – Moment of Clarity has released a new resource titled “Transcranial ...

The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...

BURLINGTON, Mass. and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...

With this expanded portfolio, our users can now choose the most appropriate coil for each specific patient, prioritizing comfort, treatment precision, and outcomes.” — Kerry Rome, SVP MagVenture, Inc.

Brainsway will prepare a submission to the FDA to market the device for OCD Deep TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD Patients who ...

Magstim Inc. received U.S. FDA clearance for use of its Horizon 3.0 and E-z Cool Coil to treat adult patients diagnosed with both obsessive compulsive disorder (OCD) and major depressive disorder (MDD ...

You are cordially invited to the Transcranial Magnetic Stimulation for Depression Awareness Group Session! Hands on Experience in the Costa Mesa/Newport Beach Office of Anew Era TMS Witness a ...